Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25385438 | 0.91 | ACHE (0.83) | ACHEMAOACES1MAOBS100A4 | |
| SCHEMBL10778357 | 0.90 | ACHE (0.81) | ACHEMAOACES1MAOBS100A4 | |
| SCHEMBL1254053 | 0.77 | ACHE (0.63) | ACHEMAOACES1MAOBS100A4 | |
| SCHEMBL13190451 | 0.76 | ACHE (0.61) | ACHEMAOACES1MAOBS100A4 | |
| SCHEMBL5258883 | 0.74 | ACHE (0.59) | ACHEMAOACES1MAOBS100A4 | |
| SCHEMBL86279 | 0.74 | ACHE (0.59) | ACHEMAOACES1MAOBS100A4 | |
| SCHEMBL31510701 | 0.74 | ACHE (0.59) | ACHEMAOACES1MAOBS100A4 | |
| SCHEMBL31123671 | 0.74 | ACHE (0.59) | ACHEMAOACES1MAOBS100A4 | |
| SCHEMBL22271438 | 0.74 | ACHE (0.59) | ACHEMAOAMAOBCA9KMT2A | |
| SCHEMBL22271588 | 0.74 | ACHE (0.59) | ACHEMAOBS100A4CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-26 | — | — | US | claimed |
| WO-2025122555-A1 | S1P 1 RECEPTOR AGONISTS AND USES THEREOF | VALO HEALTH, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2023245156-A2 | VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-12-21 | — | — | WO | claimed |
| US-20220315523-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-10-06 | — | — | US | claimed |
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4727548-A1 | METHOD OF TREATING CANCER WITH INDOLINE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4638433-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | CYTOKINETICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250296916-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-0707023-A1 | Method for the preparation of a heterocyclic polymer | DSM N.V. (NL) | 1996-04-17 | — | — | EP | disclosed |
| US-4867781-A | PRE- AND POSTEMERGENCE HERBICIDES; NONPHYTOTOXIC | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4802911-A | HERBICIDES, PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-07 | — | — | US | disclosed |
| EP-0107979-B1 | NOVEL PHENYL-SUBSTITUTED SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-10-12 | — | — | EP | disclosed |
| US-4741761-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-05-03 | — | — | US | disclosed |
| US-4620870-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| US-4586950-A | HERBICIDES | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1986-05-06 | — | — | US | disclosed |
| EP-0107979-A1 | Novel phenyl-substituted sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296916-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNI3, TNNC1 | ACHE 2931/4885MAOA 4410/4885CES1 2501/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ACHE 3200/4885MAOA 1555/4885CES1 3083/4885 |
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | SLC18A2, SLC6A2, SLC6A3 | ACHE 1656/4885MAOA 420/4885CES1 355/4885 |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | MYLK2, MUSK, MYLK | ACHE 942/4885MAOA 2894/4885CES1 2297/4885 |
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | ACHE 1398/4885MAOA 1192/4885CES1 303/4885 |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNT2, RYR1 | ACHE 828/4885MAOA 3043/4885CES1 1014/4885 |
| US-20220315523-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | SLC18A2, SLC6A2, SLC6A3 | ACHE 1019/4885MAOA 126/4885CES1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.